Equity Overview
Price & Market Data
Price: $1.44
Daily Change: -$0.09 / 6.25%
Daily Range: $1.42 - $1.54
Market Cap: $26,412,672
Daily Volume: 362,355
Performance Metrics
1 Week: -14.37%
1 Month: 26.55%
3 Months: 19.17%
6 Months: 26.55%
1 Year: -34.10%
YTD: 25.44%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: other
Country:
Details
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.